Call Options

16 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$0.14 - $695.9 $1,148 - $5.71 Million
8,200 Added 38.86%
29,300 $4,000
Q3 2022

Nov 14, 2022

SELL
$0.5 - $523.8 $2,600 - $2.72 Million
-5,200 Reduced 19.77%
21,100 $11,000
Q2 2022

Aug 15, 2022

SELL
$0.63 - $2.58 $24,255 - $99,330
-38,500 Reduced 59.41%
26,300 $23,000
Q1 2022

May 16, 2022

SELL
$1.65 - $3.12 $287,100 - $542,880
-174,000 Reduced 72.86%
64,800 $163,000
Q4 2021

Feb 14, 2022

SELL
$2.31 - $5.85 $302,841 - $766,935
-131,100 Reduced 35.44%
238,800 $616,000
Q3 2021

Nov 15, 2021

BUY
$4.55 - $10.36 $88,725 - $202,020
19,500 Added 5.57%
369,900 $1.69 Million
Q2 2021

Aug 11, 2021

BUY
$5.98 - $7.51 $468,234 - $588,033
78,300 Added 28.78%
350,400 $2.41 Million
Q1 2021

May 17, 2021

BUY
$6.98 - $11.29 $1.32 Million - $2.14 Million
189,200 Added 228.23%
272,100 $1.99 Million
Q4 2020

Feb 16, 2021

SELL
$7.81 - $10.39 $600,589 - $798,991
-76,900 Reduced 48.12%
82,900 $670,000
Q3 2020

Nov 16, 2020

BUY
$6.34 - $10.83 $447,604 - $764,598
70,600 Added 79.15%
159,800 $1.63 Million
Q2 2020

Aug 14, 2020

BUY
$4.6 - $8.6 $359,260 - $671,660
78,100 Added 703.6%
89,200 $598,000
Q2 2019

Aug 14, 2019

SELL
$6.34 - $8.8 $23,458 - $32,560
-3,700 Reduced 25.0%
11,100 $72,000
Q1 2019

May 15, 2019

BUY
$6.06 - $9.0 $13,332 - $19,800
2,200 Added 17.46%
14,800 $123,000
Q4 2018

Feb 14, 2019

SELL
$5.18 - $9.35 $19,166 - $34,595
-3,700 Reduced 22.7%
12,600 $70,000
Q3 2018

Nov 14, 2018

SELL
$6.0 - $11.35 $10,800 - $20,430
-1,800 Reduced 9.94%
16,300 $144,000
Q2 2018

Aug 14, 2018

BUY
$4.82 - $8.53 $87,242 - $154,393
18,100 New
18,100 $154,000

Others Institutions Holding RDHL

About RedHill Biopharma Ltd.


  • Ticker RDHL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 63,823,500
  • Market Cap $465M
  • Description
  • RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...
More about RDHL
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.